all projects

Value added
of German
pharmaceutical exports

Client

Roche

Year

2023


The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.

Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports. 

Pharmaceutical exports generate above-average value-added 

Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.

In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.

Germany's share of global pharmaceutical patents is declining

In terms of research, the German pharmaceutical industry is losing ground on its international competitors:

  • In terms of research and development expenditure in relation to sales, the pharmaceutical industry is among the two most research-intensive German industrial sectors. Their absolute research expenditure has also risen at an above average rate in recent years.
  • The high global innovation dynamics in the pharmaceutical research sector is also reflected in patents: during the period under review, the number of pharmaceutical patents increased twice as much as the total number of patents worldwide.
  • However, Germany as a research location was not able to keep up with this dynamic. The German share of worldwide patents has fallen noticeably in recent years, due, in particular, to a high increase in the patent activity of the Chinese and Korean research locations.
  • On the one hand, this indicates that global pressure for innovation is likely to remain high in the coming years. On the other, this is a warning signal: in the future, a relative loss of importance in terms of innovation could also lead to a relative loss of importance on the market side – marked by shrinking world export shares. 

Our approach

For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.

Links and downloads

To the study (PDF in German)

Further information, in German (Roche website)

Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss 

Latest update: 07.12.2023

Do you have questions?

Your contact at Prognos

Johann Weiß

Senior Project Manager

View profile

Mehr Studien & Projekte zu diesem Thema

More studies & projects on this topic

Guest article in SPIEGEL: How Europe's economy can catch up with the USA and China

2024
| Expertise

A race to catch up - this is what Europe needs if it is not to be left behind by the USA and China. In the SPIEGEL guest article, Christian Böllhoff calls for a new match plan with clear priorities for the new EU legislative period.

Prognos Economic Outlook® (PEO®)

ongoing
| Project

In uncertain times, there is a growing demand for orientation. PEO® delivers independent figures. Based on our wolrd economy model we project the developments until 2045.

Significance of the German economy for Europe

2024
| Project

Growth in the German economy benefits the whole of Europe. Our study for the vbw shows that this is due to the size of the economy and its strong foreign trade networks.

Employers’ attractiveness according to parents and carers

2024
| Project

Employees want tailor-made reconciliation measures that ensure work-life balance and not to face professional disadvantage as a result of their care work. These were the findings of our study for the BMFSFJ.

AI players in the federal state

2024
| Project

Which companies are already using or developing artificial intelligence? Which companies would benefit from the use of AI? Prognos created an interactive dashboard for one federal state.

Web tool: Risk analysis for sustainable supply chains

ongoing
| Project

Prognos develops a tool for an industry association that enables member companies to carry out risk analyses to identify sustainability risks in countries and sectors.

Guideline: Data management for successful sustainability reporting

2024
| Project

We have produced guidelines for successful sustainability reporting in accordance with the Corporate Sustainability Reporting Directive for an industry association. The third guide deals with data management in accordance with the CSRD.

Guidelines: With Sustainable Governance to successful sustainability reporting

2024
| Project

We have produced guidelines for successful sustainability reporting in accordance with the Corporate Sustainability Reporting Directive for an industry association. The second guide is dedicated to the topic of "Sustainability Governance".

Study on Poverty and income inequality in the context of the digital transformation

2024
| Project

The study for the European Commission examines the impact of digitalisation on the employment situation in the individual member states as well as on the EU economy as a whole.

Guest article in WirtschaftsWoche: "Move Europe - it's urgent!"

2024
| Expertise

In his guest article "Move Europe - it's urgent!" in WirtschaftsWoche, Christian Böllhoff calls for Europe to reposition itself geo-economically in order to strengthen its position between the economic giants USA and China.

About us

Prognos – Providing Orientation.

Prognos is one of the oldest economic research centres in Europe. Founded at the University of Basel, Prognos experts have been conducting research for a wide range of clients from the public and private sectors since 1959 – politically independent, scientifically sound.

Learn more